Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab vs Methylprednisolone in Active Moderate-Severe Graves' Orbitopathy
NCT04876534Phase 2Completed
- Sponsor
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
- Start
- Dec 2019
- Primary completion
- Sep 2023
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of tocilizumab in Graves' ophthalmopathy (TED) (2 arms), sponsored by Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. Primary endpoint: Proportion of patients with CAS reduction of 3 points or disease inactivation (CAS<4) at 24 weeks. Started Dec 2019; status: completed.
02
Drugs
tocilizumab
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on NCT04876534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04876534.